Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Daniel O'Connell is most often covered alongside Acumen Pharmaceuticals, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Daniel O'Connell is most often covered alongside Acumen Pharmaceuticals, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. The 7 average consequence score is above the beat benchmark of 6 in the same window. Daniel O'Connell appears in 1 tracked Biotech story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Daniel O'Connell. Shared-story counts are live from our verified record — not editorial picks.
Acumen Pharmaceuticals is advancing its lead antibody, sabirnetug, through Phase II clinical trials while leveraging a strategic partnership with JCR Pharmaceuticals for enhanced brain delivery. The company has identified 2026 as a critical catalyst year for data readouts that could validate its unique approach to targeting toxic amyloid-beta oligomers.
Daniel O'Connell is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
